

# Ramon Salazar

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2116861/publications.pdf>

Version: 2024-02-01

128  
papers

14,100  
citations

81839

39  
h-index

22147

113  
g-index

130  
all docs

130  
docs citations

130  
times ranked

19592  
citing authors

#	ARTICLE	IF	CITATIONS
1	The consensus molecular subtypes of colorectal cancer. <i>Nature Medicine</i> , 2015, 21, 1350-1356.	15.2	3,596
2	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1386-1422.	0.6	2,545
3	Gastroenteropancreatic neuroendocrine tumours. <i>Lancet Oncology</i> , The, 2008, 9, 61-72.	5.1	1,474
4	ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. <i>Neuroendocrinology</i> , 2016, 103, 172-185.	1.2	844
5	Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1291-1305.	0.6	591
6	Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 17-24.	0.8	487
7	MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF- $\beta$ 2 Receptor Signaling. <i>Cell</i> , 2012, 151, 937-950.	13.5	371
8	Personalizing Colon Cancer Adjuvant Therapy: Selecting Optimal Treatments for Individual Patients. <i>Journal of Clinical Oncology</i> , 2015, 33, 1787-1796.	0.8	303
9	Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transition. <i>International Journal of Cancer</i> , 2014, 134, 552-562.	2.3	286
10	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. <i>Cancer Discovery</i> , 2020, 10, 1465-1474.	7.7	151
11	Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer. <i>Annals of Oncology</i> , 2017, 28, 1294-1301.	0.6	150
12	Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2007, 14, 221-232.	1.6	142
13	A combined oncogenic pathway signature of <i>BRAF</i> , <i>KRAS</i> and <i>PI3KCA</i> mutation improves colorectal cancer classification and cetuximab treatment prediction. <i>Gut</i> , 2013, 62, 540-549.	6.1	121
14	Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. , 2017, 5, 71.		113
15	Genomic Classifier ColoPrint Predicts Recurrence in Stage II Colorectal Cancer Patients More Accurately Than Clinical Factors. <i>Oncologist</i> , 2015, 20, 127-133.	1.9	109
16	Aberrant gene expression in mucosa adjacent to tumor reveals a molecular crosstalk in colon cancer. <i>Molecular Cancer</i> , 2014, 13, 46.	7.9	108
17	Discovery and Validation of New Potential Biomarkers for Early Detection of Colon Cancer. <i>PLoS ONE</i> , 2014, 9, e106748.	1.1	99
18	Differences between CAFs and their paired NCF from adjacent colonic mucosa reveal functional heterogeneity of CAFs, providing prognostic information. <i>Molecular Oncology</i> , 2014, 8, 1290-1305.	2.1	98

#	ARTICLE	IF	CITATIONS
19	Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: A phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801). <i>European Journal of Cancer</i> , 2013, 49, 3780-3787.	1.3	84
20	Context matters – consensus molecular subtypes of colorectal cancer as biomarkers for clinical trials. <i>Annals of Oncology</i> , 2019, 30, 520-527.	0.6	80
21	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. <i>Lancet Oncology</i> , The, 2021, 22, 1669-1680.	5.1	73
22	A Vulnerability of a Subset of Colon Cancers with Potential Clinical Utility. <i>Cell</i> , 2016, 165, 317-330.	13.5	70
23	Gene Expression Differences between Colon and Rectum Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 7303-7312.	3.2	69
24	A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). , 2019, 7, 20.		68
25	Infectious complications in 126 patients treated with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. <i>Bone Marrow Transplantation</i> , 1999, 23, 27-33.	1.3	67
26	Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 27-34.	2.7	67
27	A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients. <i>Human Gene Therapy</i> , 2019, 30, 352-364.	1.4	66
28	Comparison and applicability of molecular classifications for gastric cancer. <i>Cancer Treatment Reviews</i> , 2019, 77, 29-34.	3.4	65
29	Lung metastases share common immune features regardless of primary tumor origin. , 2020, 8, e000491.		63
30	DPYD Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer. <i>JAMA Oncology</i> , 2016, 2, 655.	3.4	62
31	Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors. <i>Oncologist</i> , 2018, 23, 766-e90.	1.9	59
32	Phase I Clinical and Pharmacokinetic Study of Kahalalide F Administered Weekly as a 1-Hour Infusion to Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 1116-1123.	3.2	57
33	A robust genomic signature for the detection of colorectal cancer patients with microsatellite instability phenotype and high mutation frequency. <i>Journal of Pathology</i> , 2012, 228, 586-595.	2.1	55
34	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With RAS and BRAF Mutational Status. <i>JAMA Oncology</i> , 2018, 4, e173695.	3.4	55
35	Overcoming Resistance to Anti-EGFR Therapy in Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015, , e149-e156.	1.8	53
36	Exome Sequencing Reveals AMER1 as a Frequently Mutated Gene in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4709-4718.	3.2	52

#	ARTICLE	IF	CITATIONS
37	Time-Dependent COVID-19 Mortality in Patients With Cancer. <i>JAMA Oncology</i> , 2022, 8, 114.	3.4	50
38	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. <i>Lancet Oncology</i> , The, 2022, 23, 865-875.	5.1	50
39	Molecular Subtypes and the Evolution of Treatment Decisions in Metastatic Colorectal Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 231-238.	1.8	46
40	Functional patient-derived organoid screenings identify MCLA-158 as a therapeutic EGFR $\tilde{\text{A}}$ -LGR5 bispecific antibody with efficacy in epithelial tumors. <i>Nature Cancer</i> , 2022, 3, 418-436.	5.7	46
41	Geriatric Assessment Predicts Survival and Competing Mortality in Elderly Patients with Early Colorectal Cancer: Can It Help in Adjuvant Therapy Decision-Making?. <i>Oncologist</i> , 2017, 22, 934-943.	1.9	45
42	Carcinoma-associated fibroblasts affect sensitivity to oxaliplatin and 5FU in colorectal cancer cells. <i>Oncotarget</i> , 2016, 7, 59766-59780.	0.8	42
43	A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features. <i>BMC Cancer</i> , 2015, 15, 60.	1.1	41
44	Impact of circulating tumor DNA mutant allele fraction on prognosis in <i>RAS</i> mutant metastatic colorectal cancer. <i>Molecular Oncology</i> , 2019, 13, 1827-1835.	2.1	40
45	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , 2021, 150, 190-202.	1.3	37
46	Gastroenteropancreatic neuroendocrine tumors: diagnosis and treatment. <i>Annals of Gastroenterology</i> , 2013, 26, 29-36.	0.4	35
47	Clinicopathological risk factors of Stage II colon cancer: results of a prospective study. <i>Colorectal Disease</i> , 2013, 15, 414-422.	0.7	34
48	VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. , 2021, 9, e003254.		31
49	A 5-gene classifier from the carcinoma-associated fibroblast transcriptomic profile and clinical outcome in colorectal cancer. <i>Oncotarget</i> , 2014, 5, 6437-6452.	0.8	30
50	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. , 2021, 9, e002277.		30
51	Phase I study of weekly kahalalide F as prolonged infusion in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 75-83.	1.1	29
52	BRAF-induced tumorigenesis is IKK $\tilde{\text{I}}$ -dependent but NF- $\tilde{\text{I}}$ -independent. <i>Science Signaling</i> , 2015, 8, ra38.	1.6	29
53	The Evolution of Our Molecular Understanding of Colorectal Cancer: What We Are Doing Now, What the Future Holds, and How Tumor Profiling Is Just the Beginning. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , 91-99.	1.8	27
54	Translational research in neuroendocrine tumors: pitfalls and opportunities. <i>Oncogene</i> , 2017, 36, 1899-1907.	2.6	26

#	ARTICLE	IF	CITATIONS
55	Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. , 2022, 10, e003255.		26
56	Lymphocytic infiltration in stage II microsatellite stable colorectal tumors: A retrospective prognosis biomarker analysis. PLoS Medicine, 2020, 17, e1003292.	3.9	25
57	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. Clinical Cancer Research, 2021, 27, 4768-4780.	3.2	25
58	Intrinsic cancer subtypes-next steps into personalized medicine. Cellular Oncology (Dordrecht), 2015, 38, 3-16.	2.1	24
59	Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort.. Journal of Clinical Oncology, 2017, 35, 3509-3509.	0.8	24
60	Guidelines for biomarker testing in colorectal carcinoma (CRC): a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM). Clinical and Translational Oncology, 2012, 14, 726-739.	1.2	23
61	Factors Predicting Adherence to a Tailored-Dose Adjuvant Treatment on the Basis of Geriatric Assessment in Elderly People With Colorectal Cancer: A Prospective Study. Clinical Colorectal Cancer, 2018, 17, e59-e68.	1.0	21
62	Phase II study of high-sensitivity genotyping of KRAS, NRAS, BRAF and PIK3CA to ultra-select metastatic colorectal cancer patients for panitumumab plus FOLFIRI: the ULTRA trial. Annals of Oncology, 2019, 30, 796-803.	0.6	21
63	Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer. BMC Cancer, 2015, 15, 59.	1.1	20
64	Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. European Journal of Cancer, 2022, 171, 64-74.	1.3	19
65	A phase I and pharmacokinetic study of elisidepsin (PM02734) in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2012, 70, 673-681.	1.1	18
66	Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy. Annals of Oncology, 2019, 30, 439-446.	0.6	18
67	Molecular targeted therapies in the treatment of gastroenteropancreatic neuroendocrine tumors. Targeted Oncology, 2009, 4, 287-296.	1.7	16
68	A Monotonic and Prognostic Genomic Signature from Fibroblasts for Colorectal Cancer Initiation, Progression, and Metastasis. Molecular Cancer Research, 2014, 12, 1254-1266.	1.5	16
69	Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in <i>NRAS</i> -mutant metastatic colorectal cancer. Oncotarget, 2016, 7, 82185-82199.	0.8	16
70	Nanofluidic Digital PCR and Extended Genotyping of <i>RAS</i> and <i>BRAF</i> for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies. Molecular Cancer Therapeutics, 2016, 15, 1106-1112.	1.9	15
71	RET-fusions: a novel paradigm in colorectal cancer. Annals of Oncology, 2018, 29, 1340-1343.	0.6	15
72	Phase I clinical and pharmacokinetic study of trabectedin and carboplatin in patients with advanced solid tumors. Investigational New Drugs, 2012, 30, 616-628.	1.2	14

#	ARTICLE	IF	CITATIONS
73	Phase Ib/II study of elisidepsin in metastatic or advanced gastroesophageal cancer (IMAGE trial). <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 819-827.	1.1	14
74	Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial. <i>Annals of Oncology</i> , 2018, 29, 439-444.	0.6	14
75	Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis. <i>International Journal of Cancer</i> , 2020, 147, 2303-2315.	2.3	14
76	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. <i>Journal of the National Cancer Institute</i> , 2022, 114, 979-987.	3.0	14
77	DNA methylation events in transcription factors and gene expression changes in colon cancer. <i>Epigenomics</i> , 2020, 12, 1593-1610.	1.0	13
78	Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology. <i>Clinical and Translational Oncology</i> , 2020, 22, 1976-1991.	1.2	13
79	RAMSETE: A single-arm, multicenter, single-stage phase II trial of RAD001 (everolimus) in advanced and metastatic silent neuro-endocrine tumours in Europe.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4122-4122.	0.8	13
80	The 40S-LARP1 complex reprograms the cellular translome upon mTOR inhibition to preserve the protein synthetic capacity. <i>Science Advances</i> , 2021, 7, eabg9275.	4.7	13
81	Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer. <i>Molecular Cancer Therapeutics</i> , 2017, 16, 1999-2007.	1.9	12
82	Potential Synergies for Combined Targeted Therapy in the Treatment of Neuroendocrine Cancer. <i>Drugs</i> , 2011, 71, 841-852.	4.9	11
83	Phase I study of weekly plitidepsin as 1-hour infusion combined with carboplatin in patients with advanced solid tumors or lymphomas. <i>Investigational New Drugs</i> , 2011, 29, 1406-1413.	1.2	11
84	Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. <i>Clinical and Translational Oncology</i> , 2015, 17, 264-273.	1.2	11
85	Persistence of long-term COVID-19 sequelae in patients with cancer: An analysis from the OnCovid registry. <i>European Journal of Cancer</i> , 2022, 170, 10-16.	1.3	11
86	Streptozotocin, 1982-2022: Forty Years from the FDA's Approval to Treat Pancreatic Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2022, 112, 1155-1167.	1.2	11
87	Phase II study of preoperative bevacizumab, capecitabine, and radiotherapy for resectable locally advanced rectal cancer.. <i>Journal of Clinical Oncology</i> , 2011, 29, 516-516.	0.8	10
88	Optimizing Anti-EGFR Therapy in Colorectal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5415-5416.	3.2	9
89	Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms. <i>Neuroendocrinology</i> , 2019, 108, 18-25.	1.2	9
90	3180 Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. <i>Annals of Oncology</i> , 2020, 31, S1366.	0.6	9

#	ARTICLE	IF	CITATIONS
91	Phase II randomized trial of capecitabine with bevacizumab and external beam radiation therapy as preoperative treatment for patients with resectable locally advanced rectal adenocarcinoma: long term results. BMC Cancer, 2020, 20, 1164.	1.1	7
92	Identifying causal models between genetically regulated methylation patterns and gene expression in healthy colon tissue. Clinical Epigenetics, 2021, 13, 162.	1.8	6
93	Mutanome and expression of immune response genes in microsatellite stable colon cancer. Oncotarget, 2016, 7, 17711-17725.	0.8	6
94	Phase II study of preoperative radiotherapy and concomitant weekly intravenous oxaliplatin combined with oral capecitabine for stages II-III rectal cancer. Clinical and Translational Oncology, 2012, 14, 592-598.	1.2	5
95	Complete and Sustained Objective Response per RECIST to Irvallec (PM02734) in Undifferentiated Large Cell Esophageal Adenocarcinoma: A Case Report and a Review of the Literature. Case Reports in Oncology, 2012, 5, 354-358.	0.3	5
96	New Approaches but the Same Flaws in the Search for Prognostic Signatures. Clinical Cancer Research, 2014, 20, 2019-2022.	3.2	5
97	Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemoradiotherapy before surgery in patients with locally advanced rectal cancer: is it ready for primetime?. Annals of Oncology, 2018, 29, 532-534.	0.6	5
98	The PARSC trial, a prospective study for the assessment of recurrence risk in stage II colon cancer (CC) patients using ColoPrint.. Journal of Clinical Oncology, 2012, 30, 678-678.	0.8	5
99	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110534.	1.4	5
100	Molecular markers in colorectal cancer: clinical relevance in stage II colon cancer. Colorectal Cancer, 2013, 2, 243-263.	0.8	4
101	Paracrine Network: Another Step in the Complexity of Resistance to EGFR Blockade?. Clinical Cancer Research, 2014, 20, 6227-6229.	3.2	4
102	Pancreatic NETs: where do we stand now?. Cancer and Metastasis Reviews, 2014, 33, 361-366.	2.7	4
103	Prognosis and Therapeutic Implications for Emerging Colorectal Cancer Subtypes. Current Colorectal Cancer Reports, 2014, 10, 55-61.	1.0	4
104	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110422.	1.4	4
105	Study on activation of the IGF-1R mTOR pathway in neuroendocrine tumours (NETs).. Journal of Clinical Oncology, 2013, 31, 4139-4139.	0.8	4
106	Fooled by Randomness. The Misleading Effect of Treatment Crossover in Randomized Trials of Therapies with Marginal Treatment Benefit. Cancer Investigation, 2022, 40, 184-188.	0.6	4
107	Selective activity over a constitutively active RET variant of the oral multikinase inhibitor dovitinib: Results of the CNIO BR002 phase I trial. Molecular Oncology, 2014, 8, 1719-1728.	2.1	3
108	A phase I trial of oncolytic adenovirus ICOVIR-5 administered intravenously to melanoma patients. Human Gene Therapy Clinical Development, 2018, . .	3.2	3

#	ARTICLE	IF	CITATIONS
109	Three Versus Six Months of Adjuvant Doublet Chemotherapy for Patients With Colorectal Cancer: A Multi-Country Cost-Effectiveness and Budget Impact Analysis. <i>Clinical Colorectal Cancer</i> , 2021, 20, 236-244.	1.0	2
110	Genomic classifier (ColoPrint) to predict outcome and chemotherapy benefit in stage II and III colon cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3612-3612.	0.8	2
111	Comparison of ColoPrint risk classification with clinical risk in the prospective PARSC trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 465-465.	0.8	2
112	Expression of the insulin gene is regulated by opioid peptides. <i>Biomedica Biochimica Acta</i> , 1990, 49, 1165-70.	0.1	2
113	A phase I clinical and pharmacokinetic study (LIPOTEC - GP PHARM/DOXO 01) of a new liposomal doxorubicin given as 3-week schedule in patients with solid tumors. <i>Journal of Liposome Research</i> , 2009, 19, 261-266.	1.5	1
114	Phase I study of carboplatin in combination with PM00104 (Zalypsis <sup>®</sup> ) in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 644-652.	1.2	1
115	Light and shade of intrahepatic arterial radiotherapy in mCRC. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 467-468.	12.5	1
116	DPYD genotype-guided fluoropyrimidines dose: is it ready for prime time?. <i>Annals of Oncology</i> , 2017, 28, 2913-2914.	0.6	1
117	Bayesian interpretation of the ESMO guideline for localized colorectal cancer: a better IDEA. <i>Annals of Oncology</i> , 2021, 32, 938-939.	0.6	1
118	Potential role of mTOR phosphorylation status as a negative predictor to everolimus plus octreotide in NETs.. <i>Journal of Clinical Oncology</i> , 2014, 32, 484-484.	0.8	1
119	Prognostic value of PAM50 in residual breast cancer following neoadjuvant endocrine therapy (NET): A retrospective analysis with long follow-up.. <i>Journal of Clinical Oncology</i> , 2019, 37, 575-575.	0.8	1
120	Tenth anniversary of bevacizumab in colorectal cancer: has it fulfilled its promise?. <i>Future Oncology</i> , 2014, 10, 149-152.	1.1	0
121	SUNRISE-DI study. The daily sunrise is easier to predict than the benefit of adjuvant treatment in colon cancer. <i>ESMO Open</i> , 2021, 6, 100205.	2.0	0
122	Olaratumab-induced Biomarker Modulation in Sarcomas <sup>®</sup> Letter. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 2093-2093.	1.9	0
123	Phase I combination study of plitidepsin and carboplatin in advanced solid tumours. <i>Journal of Clinical Oncology</i> , 2007, 25, 2558-2558.	0.8	0
124	Development and validation of a genomic signature to identify colorectal cancer patients with microsatellite instability.. <i>Journal of Clinical Oncology</i> , 2012, 30, 466-466.	0.8	0
125	<i>hSRBC</i> promoter CpG island hypermethylation as resistant predictive biomarker of oxaliplatin based chemotherapy in metastatic colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, e14609-e14609.	0.8	0
126	Association of colorectal cancer intrinsic subtypes with prognosis, chemotherapy response, deficient mismatch repair, and epithelial to mesenchymal transition (EMT).. <i>Journal of Clinical Oncology</i> , 2013, 31, 3530-3530.	0.8	0



#	ARTICLE	IF	CITATIONS
127	Duloxetine in symptomatic chemotherapy-induced peripheral neuropathy: Single-center experience beyond the clinical trial.. Journal of Clinical Oncology, 2015, 33, e20713-e20713.	0.8	0
128	Prospective Multicentric Observational Study of COVID19 in Oncohematological Patients in the Catalonia Region: The Opposite Effect of Steroids on Survival. Blood, 2020, 136, 34-35.	0.6	0